Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, one processes involved in pathophysiology AD, has inspired interest targeted therapies, including monoclonal antibodies. Aducanumab acts as a fully human IgG1 antibody against Aβ by binding to amyloid plaques and was approved Food Drug Administration (FDA) first disease-modifying drug for...